Hasil Pencarian - Hang Quach

Perbaiki Hasil
  1. 1
    Multiplex immunohistochemistry elucidates increased distance between cytotoxic T cells and plasma cells in relapsed myeloma, and identifies Lag-3 as the most common checkpoint receptor on cytotoxic T cells of myeloma patients

    Multiplex immunohistochemistry elucidates increased distance between cytotoxic T cells and plasma cells in relapsed myeloma, and identifies Lag-3 as the most common checkpoint rece... oleh Slavisa Ninkovic, Louise E. Purton, Simon J. Harrison, Hang Quach

    Diterbitkan 2023-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Comment on “Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma”

    Comment on “Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma” oleh Simon J. Harrison, Hang Quach, Andrew Spencer, H. Miles Prince

    Diterbitkan 2015-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Conventional Treatment for Multiple Myeloma Drives Premature Aging Phenotypes and Metabolic Dysfunction in T Cells

    Conventional Treatment for Multiple Myeloma Drives Premature Aging Phenotypes and Metabolic Dysfunction in T Cells oleh Rachel Elizabeth Cooke, Rachel Elizabeth Cooke, Kylie Margaret Quinn, Hang Quach, Hang Quach, Simon Harrison, Simon Harrison, Henry Miles Prince, Henry Miles Prince, Rachel Koldej, Rachel Koldej, David Ritchie, David Ritchie, David Ritchie

    Diterbitkan 2020-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    P983: DREAMM-20: A STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF BELANTAMAB FOR THE TREATMENT OF MULTIPLE MYELOMA WHEN USED AS MONOTHERAPY AND IN COMBINATION TREATMENTS

    P983: DREAMM-20: A STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF BELANTAMAB FOR THE TREATMENT OF MULTIPLE MYELOMA WHEN USED AS MONOTHERAPY AND IN COMBINATION TREATMENTS oleh Hang Quach, Giulia Fulci, Nirav Ratia, John Clements, Eric Lewis, Malika Ahras, Sarantos Kaptanis, Brandon E. Kremer

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Circulating tumor DNA and bone marrow minimal residual disease negativity confers superior outcome for multiple myeloma patients

    Circulating tumor DNA and bone marrow minimal residual disease negativity confers superior outcome for multiple myeloma patients oleh Sridurga Mithraprabhu, John Reynolds, Hang Quach, Noemi Horvath, Ian Kerridge, Tiffany Khong, Brian GM Durie, Andrew Spencer

    Diterbitkan 2023-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    P908: IDENTIFICATION OF CYTOKINES ASSOCIATED WITH RESPONSE AND CYTOKINE RELEASE SYNDROME – ANALYSIS OF MAGNETISMM-3 COHORT A

    P908: IDENTIFICATION OF CYTOKINES ASSOCIATED WITH RESPONSE AND CYTOKINE RELEASE SYNDROME – ANALYSIS OF MAGNETISMM-3 COHORT A oleh Katja Weisel, Nizar J Bahlis, Paula Rodríguez-Otero, Andrea Viqueira, Shen-Wu Wang, Sangeetha Sathiah, Douglas Robinson, Thomas O’brien, Hang Quach

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    P906: GENOMIC ANALYSIS TO IDENTIFY DETERMINANTS OF INHERENT RESPONSE AND RESISTANCE TO ELRANATAMAB IN MAGNETISMM-3 COHORT A

    P906: GENOMIC ANALYSIS TO IDENTIFY DETERMINANTS OF INHERENT RESPONSE AND RESISTANCE TO ELRANATAMAB IN MAGNETISMM-3 COHORT A oleh Paula Rodríguez-Otero, Hang Quach, Katja Weisel, Andrea Viqueira, Shen-Wu Wang, Phineas T. Hamilton, Tao Xie, Thomas O’brien, Nizar J Bahlis

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma

    Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma oleh Sridurga Mithraprabhu, John Reynolds, Rose Turner, Hang Quach, Noemi Horvath, Ian Kerridge, Anna Kalff, Krystal Bergin, Jay Hocking, Flora Yuen, Tiffany Khong, Brian M. Durie, Andrew Spencer

    Diterbitkan 2023-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    PB2132: EXCALIBER-RRMM: A PHASE 3, TWO-STAGE STUDY OF IBERDOMIDE, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

    PB2132: EXCALIBER-RRMM: A PHASE 3, TWO-STAGE STUDY OF IBERDOMIDE, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACT... oleh Sagar Lonial, Hang Quach, Meletios A. Dimopoulos, Paula Rodríguez-Otero, Jesus Berdeja, Paul Richardson, Margee Kyada, Shuyu Chu, Min Chen, Patricia Abad, Juliane Morando, Niels W.C.J. van de Donk

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

    PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULT... oleh Katja Weisel, Vania Hungria, Hang Quach, Sung-Soo Yoon, Paula Rodríguez-Otero, Glenn Kroog, Arijit Sinha, Anita Boyapati, Charlotte Lyon, Karen Rodriguez Lorenc, Timothy Inocencio, James Harnett, Lei Chi, Vygngley Moore, Peter Voorhees

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14)

    Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14) oleh Anna Kalff, Tiffany Khong, Malarmathy Ramachandran, P Joy Ho, Peter Mollee, James D’Rozario, Kerry Taylor, Jane Estell, Sam Norton, Roslyn Kemp, Andrew J. Mitchell, John Reynolds, Nola Kennedy, Hang Quach, Andrew Spencer

    Diterbitkan 2021-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry

    Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry oleh Krystal Bergin, Elizabeth Moore, Zoe McQuilten, Erica Wood, Bradley Augustson, Hilary Blacklock, Joy Ho, Noemi Horvath, Tracy King, John McNeil, Peter Mollee, Hang Quach, Christopher M. Reid, Brian Rosengarten, Patricia Walker, Andrew Spencer

    Diterbitkan 2016-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    A multi-center, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma

    A multi-center, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma oleh Hang Quach, Gurdeep Parmar, Enrique M. Ocio, H. Miles Prince, Albert Oriol, Helen Crowther, Nobuhiro Tsukada, Pierre Bories, Sumit Madan, Nitya Nathwani, Kazutaka Sunami, Dorothee Semiond, Disa Yu, Paul Cordero, Sandrine Macé, Florence Suzan, Philippe Moreau

    Diterbitkan 2024-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma

    Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma oleh Torben Plesner, Simon J. Harrison, Hang Quach, Cindy Lee, Adam Bryant, Annette Vangsted, Jane Estell, Michel Delforge, Fritz Offner, Patrick Twomey, Voleak Choeurng, Junyi Li, Robert Hendricks, Shannon M. Ruppert, Teiko Sumiyoshi, Karen Miller, Eunpi Cho, Fredrik Schjesvold

    Diterbitkan 2023-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma

    A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma oleh Karthik Ramasamy, Ajay Nooka, Hang Quach, Myo Htut, Rakesh Popat, Michaela Liedtke, Sascha A. Tuchman, Jacob Laubach, Cristina Gasparetto, Asher Chanan-Khan, Mark Hertzberg, Mark deMario, Eveline Nueesch, Evelyne Chesne, Izolda Franjkovic, Katharina Lechner, Martin Kornacker, Hearn Jay Cho

    Diterbitkan 2021-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    S196: ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM MAGNETISMM-3

    S196: ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATIO... oleh Mohamad Mohty, Michael H. Tomasson, Bertrand Arnulf, Nizar J Bahlis, Paula Rodríguez-Otero, Joaquín Martinez-Lopez, Cyrille Touzeau, Hang Quach, Julien Depaus, Hisayuki Yokoyama, Salomon Manier, Noopur Raje, Marc S. Raab, Emma Searle, Eric Leip, Sharon T. Sullivan, Akos Czibere, Andrea Viqueira, Alexander Lesokhin

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    P868: MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE DOSE-EXPANSION PHASE OF THE CC-92480-MM-001 TRIAL

    P868: MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE DOSE-EXPANSION PHASE OF THE CC-92480-MM-001 T... oleh Nizar J Bahlis, Suzanne Trudel, Hang Quach, Rakesh Popat, Sagar Lonial, Robert Z Orlowski, Kihyun Kim, Maria-Victoria Mateos, Charlotte Pawlyn, Karthik Ramasamy, Joaquín Martinez-Lopez, Ignacio Casas-Avilés, Alessia Spirli, Jing Gong, Michael Amatangelo, Jessica Katz, Paulo Maciag, Teresa Peluso, Paul Richardson

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    The prognostic impact of t(11;14) in multiple myeloma: A real‐world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR)

    The prognostic impact of t(11;14) in multiple myeloma: A real‐world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Reg... oleh Kenneth JC Lim, Cameron Wellard, Dipti Talaulikar, Joanne LC Tan, Joanna Loh, Pratheepan Puvanakumar, James A Kuzich, Michelle Ho, Matthew Murphy, Nicole Zeglinas, Michael SY Low, David Routledge, Andrew BM Lim, Simon D Gibbs, Hang Quach, Sue Morgan, Elizabeth Moore, Slavisa Ninkovic

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial

    Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial oleh Meletios A. Dimopoulos, Fredrik Schjesvold, Vadim Doronin, Olga Vinogradova, Hang Quach, Xavier Leleu, Yolanda Gonzalez Montes, Karthik Ramasamy, Alessandra Pompa, Mark-David Levin, Cindy Lee, Ulf Henrik Mellqvist, Roland Fenk, Hélène Demarquette, Hamdi Sati, Alexander Vorog, Richard Labotka, Jichang Du, Mohamed Darif, Shaji Kumar

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    P865: TECLISTAMAB IN COMBINATION WITH LENALIDOMIDE IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA IN THE PHASE 1B MULTICOHORT MAJESTEC-2 STUDY

    P865: TECLISTAMAB IN COMBINATION WITH LENALIDOMIDE IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA IN THE PHASE 1B MULTICOHORT MAJESTEC-2 STUDY oleh Carlyn Tan, Emma Searle, Sébastien Anguille, Manisha Bhutani, Noa Biran, Kevin Boyd, Andrew Cowan, Jeffrey Matous, Aurore Perrot, Jesus Berdeja, Wojciech Janowski, Rakesh Popat, Hang Quach, Mark Schroeder, Sandy W Wong, Deeksha Vishwamitra, Yue Guo, Zhuolu Niu, Julie Larsen, Lingling Chen, Arnob Banerjee, Cyrille Touzeau

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: